labcorp america hold
labcorp america lead provid diagnost test inform servic
lh report in-lin result top-lin driven organ growth
covanc busi labcorp diagnost test busi face
known headwind greater pama impact shift test
volum commerci contract issu plagu
compani toward end normal launchpad cost save
could help mitig headwind compani face year despit
solid perform covanc drug develop busi plan
deploy free cash flow share repurchas
maintain hold rate moder organ growth diagnost
busi suggest share fairli valu view
result nutshel revenu increas y/i
in-lin consensu modestli lower
estim bright spot covanc drug develop busi
grew revenu organ strong book-to-bil
expand adjust oper margin bp hand
labcorp diagnost revenu decreas larg due neg
impact divest covanc food solut busi adjust ep
higher consensu ahead estim
beat larg come higher gross margin
labcorp diagnost growth pressur lh diagnost revenu
decreas modestli higher
estim exclud impact divest busi test volum
grew bp better estim contribut
bp volum organ volum decreas bp adjust
advers weather y/i calendar impact organ volum would
increas revenu per requisit decreas bp adjust
divestitur better estim pama
neg bp impact price fx creat bp headwind
y/i modestli estim organ
revenu growth acquisit contribut fx
bp headwind ttm net order increas net
book-to-bil improv modestli sequenti basi book-to-
bill covanc adjust oper margin improv bp y/i
driven organ growth acquisit launchpad cost save
partial off-set personnel cost backlog end
expect convert revenu next month
